Skip to main content

ACR 2026 RheumNow Lupus Topic Compilation a

Nov 16, 2026 2:45 pm
Statins and eGFR in SLE Long-term Opioid Use in Lupus Does Obesity Play a Role Two targets or one CAR-T in Lupus Nephritis Hydroxychloroquine Blood Levels and Retinopathy Risk When Low Cardiovascular Risk Misses Coronary Plaque Low PREVENT Score, Real Risk Coronary Calcium and Heart Failure in Lupus SGLT2 Inhibitors in Lupus Nephritis Lupus Remission is not one Single Thing

Transcription

This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.

Go to roomnow.live to see the full program and register today.

Hello. I'm Sheila Reyes from The Philippines reporting for RheumNow here at the ACR twenty twenty six in sunny Orlando, Florida. This time, I will be talking about abstract number zero nine two three, which I found really interesting. And this is from the group of doctor Faith Obillo, who talked about or examined the effects of statins in eGFR of lupus patients. So they wanted to determine the association between statin use and the annual GFR slope, in SLE patients with or without lupus nephritis.

They examined a large population of patients, more than a thousand patients with lupus, without nephritis and about ninety four with incident biopsy proven lupus nephritis. And they also had a long exposure, study period spanning from 2013 up to 2025. Now what were the findings of their study? Well, interestingly enough, they found two opposing or different results. First, in patients without lupus nephritis, statin use slowed the annual eGFR decline.

And secondly, in patients with biopsy proven lupus nephritis, there was no significant effect of statins on the eGFR decline. Now what are the possible implications of these results in clinical practice? The role of statins are already established in the treatment and management of SLE, and I think stratifying patients who will benefit from treatment from these drugs should always be considered regularly assessed and monitored. Thank you. I'm Sheila Reyes.

Follow me on x at RheumOrampA, and tune into RheumNow for more updates with ACR twenty twenty six.

Hi everyone. My name is Akhil Sood reporting for RheumNow. Chronic pain, including long term opioid use, is common among individuals with lupus. Various factors like long standing disease, organ damage, and even depression can contribute to this chronic pain. But where does obesity fit into the picture?

Abstract 30,023 seeks to evaluate this. Through a retrospective longitudinal cohort, they evaluated whether baseline obesity, defined as a BMI of thirty or higher, is associated with long term opioid prescription, defined as two or more consecutive prescriptions of opioids through any time of the survey. About a third of the individuals were obese and factors like depression, functional disability status, as well as pain were higher among obese individuals. And they found that compared to non obese individuals, obesity was associated with nearly two fold increased risk of long term opioid prescription. And when adjusting for disease activity, the risk was attenuated, but the risk was still increased.

So what do we take from this? The findings from the study are interesting and worth important consideration, but I would interpret it cautiously. The findings were collected from a survey that was largely self reported. We don't know whether the prescriptions were actually taken by the patient, who prescribed the medication, and what was the indication for the prescription. And when it comes to managing obesity for individuals with lupus, how should we treat it?

Should we use medication? Lifestyle changes? And I think for that answer, I think we need take a step further back and understand where obesity fits in the overall lupus journey. For many individuals with lupus and long standing disease and long standing steroid use, there's a risk of weight gain and limited mobility, and this can contribute to chronic pain. Furthermore, obesity may be increased by food insecurity, which can heighten the risk.

So when it comes to addressing obesity in the clinic, it's important to understand what drives this and that may inform the next steps. This is Akhil Sood reporting for you now. Thank you.

Hello, I'm Ehike Damoni. I'm a rheumatologist from Sao Paulo and I'm in the coverage of ACL twenty twenty six by RheumNow. Today I'm going to talk about dual target therapy especially using CAR T therapy for lupus nephritis. First, the idea. Most CAR T in lupus targets only CD19, which removes B cells.

But some plasma cells do not have CD19. They can survive and keep making antibodies, but a second target like BCMA can remove these cells too. So the goal is to get a deeper result. Abstract one to 15, a suit from China, tests a CAR T against CD19 and BCMA. So we are talking about dual target CAR T.

It is off the shelf. It's made from a health donor. 16 patients with lupus nephritis, especially talking about the results right now, eleven of them have achieved complete renal response. Sixty nine percent of the patients at nine months. All patients were on five milligrams of prednisone or less.

CRS was mute and these patients did not have any neurotoxicity because of the treatment. So what's my read? My read is that to talking about CD19 and BCMA makes sense, two targets makes sense because some auto antibodies are productive by plasma cells so only achieving CD19 cannot bring the right result for these patients. Another point that is important is that this is an off the shelf therapy so a lot of patients can receive these without needing some stay at the hospital or time for manufacture. So I'm Ehike Dominique.

I'm very glad to be with you here at RheumNow. Thank you.

Hello. I'm Sheila Reyes from The Philippines reporting for RheumNow here at the ACR twenty twenty six in Orlando, Florida. I would like to talk about abstract number twelve twenty three from the group of doctor Shivani Garg on hydroxychloroquine levels and the risk of retinopathy. Using a target trial emulation network from three SLE cohorts, they evaluated whether there was an association between hydroxychloroquine blood levels and weight based dosing and the risk of retinopathies. And they tested two thresholds in parallel.

So that's the hydroxychloroquine dose of less than or equal to five milligram per kilo or the more than five milligram per kilo and hydroxychloroquine blood levels less than or equal to 1,150 nanograms per ml or more than 1,150 nanograms per ml. And what did they see? The dose based thresholds were not associated with retinopathy. However, using the hydroxychloroquine blood levels with levels more than one thousand one hundred fifty nanograms per ml, the risk for retinopathy was two point four times higher than for levels less than one thousand one hundred fifty nanograms per ml. What's my key takeaway from this study?

We are now seeing an increasing number of evidence supporting the emerging role of hydroxychloroquine blood level monitoring and should now be considered in clinical practice, especially in assessing retinopathy risk. Because hydroxychloroquine blood level monitoring is available in the area where I practice in my country, evaluating its clinical correlation within our local demographic would be interesting to explore. Thank you. Follow me on x at RheumNow for more updates of ACR twenty twenty six.

Hi. I'm Melissa Axelrod. I'm a fellow at Columbia University and I'm going to be talking about Abstract nine twenty two presented by Landim and his colleagues, which was examining the coronary artery calcification in patients with lupus, classified as low cardiovascular risk by the new PREVENT calculator. So the question here is simple but clinically important. When our patients have a low calculated cardiovascular risk, do we just forget about it and be reassured?

So the 2026 ACC guidelines recommend the PREVENT calculator to estimate future atherosclerotic cardiovascular events. Lupus is recognized in and of itself as a cardiovascular risk factor enhancing condition, but it isn't directly incorporated into the equation. And as rheumatologists, we know that chronic inflammation, accumulated organ damage, and treatment exposure may contribute to cardiovascular risk beyond traditional risk factors. The investigators studied eighty three women ages 40 to 60 without known cardiovascular risk at a tertiary lupus center in Brazil. And here's what the headline found.

Sixty patients were categorized as low risk, meaning a predicted ten year ASCVD risk score less than three percent. Twelve of those sixty, which is about one fifth, had detectable coronary artery calcium scores. So they would have been ignored on a prevent score and yet when we looked at the imaging it showed that they were finding coronary calcifications. So what do we think this tells us? It tells us to keep looking and not just ignore a low PREVENT score.

Most importantly, PREVENT predicts cardiovascular events while the study measured coronary calcium at a single point in time. So does this mean we should order coronary calcium scans for every lupus patient with a low prevent score? Not necessarily, but also what I think was interesting is it started for patients age 40 to 60 and that's forgetting about the 30 year olds. My biggest takeaway is that the low calculated cardiovascular risk does not necessarily mean an absence of coronary atherosclerosis and lupus. So we have some next steps to take, and we'll see a bit more next convergence.

Hi, my name is Eikle Sood reporting for RheumNow. When it comes to the quality of care, it's important to understand how well the available tools recommended by national societies apply to our patients. Take cardiovascular risk for example. The American College of Cardiology and the American Heart Association recommend the use of the prevent risk calculator to estimate cardiovascular risk. What about in conditions like lupus?

Contract 2861 evaluated how well the prevent risk calculator performs in patients with lupus. They used a large national database of patients with lupus between the ages of 30 to 79 during the period two thousand to twenty twenty one. They inputted different clinical variables into the calculator and estimated the prevent risk of total cardiovascular disease and heart failure. And what were the key findings? The prevent models seem to underperform or underestimate cardiovascular risk and heart failure at a moderate performance.

And the sensitivity to screen for heart failure was at around fifty three percent and the sensitivity screen for total cardiovascular disease was sixty seven percent. And when it came to the predicted risk versus the observed risk, the predicted risk was lower than the observed risk across different deciles. So what's the key takeaway? The PREVENT score seems to underestimate the risk of cardiovascular disease in patients with lupus. And this complements findings from an earlier abstract presented on Sunday, abstract nine twenty two which also found a discrepancy between a low prevent score and the presence of coronary artery calcification in patients with lupus And taken together, these abstracts do raise concern that the PREVENT score may underestimate true cardiovascular risk in patients with lupus.

My takeaway is that calculating your risk score only tells part of the story. We also need to understand how well that score works to the patient that's sitting in front of us. And these findings do make me cautious about treating a low prevent score as reassurance in lupus. In my practice, I would interpret the score alongside patients' lupus history, their disease activity, glucocorticoid use, and as well as their antiphospholipid antibody status. And how to incorporate those factors into cardiovascular risk prediction remains an uncertain question.

For now, my takeaway is that a low prevent score may not tell the whole story in lupus and providing quality care means understanding the limitations of the tools and interpreting those results in the context of the patient in front of us. Name is Akhil Sood reporting for RheumNow. Thank you.

Hello. I'm Sheila Reyes from The Philippines reporting for RheumNow here at the ACR in sunny Orlando, Florida. It's day two of the conference, and lots and lots of abstracts and studies and learnings have come through. And in this video report, I would like to share some of my key takeaways from abstract number one eight six seven from the group of doctor Gurjat Singh on the renal outcomes of SGLT2 inhibitors in patients with lupus nephritis who are nondiabetic. And this was a retrospective cohort study using the TriNet research network that evaluated patients with lupus nephritis, and, they were stratified into SGLT2 inhibitor users and those who were nonusers of SGLT2 inhibitors.

And, of course, patients with diabetes were excluded in the study. And what did their results show? The investigators found that the use of SGLT two inhibitors was associated with a consistently lower three year cumulative event rates for ESRD, dialysis, heart failure, acute kidney injury, and high grade proteinuria. I think these are clinically relevant findings because it provides real world data and supports the use of SGLT2 inhibitors in patients with lupus nephritis who are non diabetic and offers, additional non immunologic renal protective treatment for these subsets of patients. As a clinician, I have patients with lupus nephritis who are non diabetic and who are also co managed with nephrology on SGLT2 inhibitors.

And because this is a retrospective study, it would be interesting to look forward, to prospective studies that may provide more robust data on these patient population, particularly those without diabetes. Thank you. Follow me on X at RheumNow for more updates of the ACR twenty twenty six.

Hi. My name is Al Kim from WashU Medicine in St. Louis, Missouri, where I direct the Lupus Center there, and I'm here at ACR twenty twenty six Convergence in Orlando, Florida. This is... The topic I wanna talk a bit...

About today is the concept of remission because there's a bunch of abstracts here that challenge our way of thinking about remission. Not necessarily it being a single state, but actually multiple different variables within a possible single state and they don't always agree. So I want to first start in the tissue. The ReBioLoop repeat biopsy data which is abstract eighteen sixty two entitled Post Treatment Portinuria and Perfectly Predicts histologic remission lupus nephritis. I think you know what I mean when I just said that title.

They have very clear evidence that post treatment proteinuria is very poorly correlative with histologic remission. And this builds on prior post hoc data analyses done within the Regency trial which was the phase three obinutuzumab lupus nephritis trial where we're also seeing some discordances. So the beautiful thing about these type of studies is that the biopsy were obtained on a per protocol basis so they've been very tightly phenotyped, well timed out. Abstracts eighteen sixty three extends on this one entitled Quantifying the Impact of Histologic Activity on proteinuria and renal outcomes in lupus nephritis. As the title also suggests, they found that the majority of proteinuria values don't necessarily associate with histologic remission at the tissue level and again extending on several other observations in the back.

So really taken together we are just gathering more and more evidence about how poor conventional urinary biomarkers are for assessing lupus nephritis and its monitoring. Then there is a third axis that neither those other two abstracts captures. This is abstract twelve thirty two. Obinutuzumab facilitates tubular repair and LN independent histologic or clinical response. This is another post hoc analysis of that Regency trial I had just previously mentioned.

What they show is that tubular repair is measured by urinary eGFR and this repair is independent of histologic activity. Think about that you can have someone with active disease but no e g f in the kidney and have no repair. You can have someone with histologic remission but no EGF in urine which also means they aren't repairing. They could also have active disease but have EGF in urine which indicates repair. You can see how complicated this is getting and it's it's it's a really interesting way to think about how we are starting to measure remission, not just in terms of injury, but also in terms of repair.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×